 This is a pilot study that will determine the endoscopic recurrence of Crohns disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative vedolizumab Entyvio or placebo. The investigators hypothesize that the administration of post-operative vedolizumab will decrease the endoscopic recurrence of Crohns disease. 